The role of conservative treatment in morbid obesity (minireview)

Research article: The role of conservative treatment in morbid obesity (minireview)
Author (s): E.A. Abdinov

Azerbaijan Medical University, 23 Bakikhanov Str., Baku AZ 1022, Azerbaijan 

For correspondence: dr.abdinov@gmail.com

Received: October 30, 2020; Received in revised form: March 21, 2021; Accepted: May 03, 2021 

Abstract

The article analyzes the treatment of long-term weight increment, morbid obesity and non-alcoholic steatohepatosis of the liver through medication, diet, lifestyle changes, and physical activity. An analysis of the literary data suggests that at morbid obesity, lifestyle changes, increased physical activity, different diets, or medications do not provide a basis for complete cure of the disease. After stopping taking both drugs and cures to reduce body weight, it begins to increase again. 

Keywords: Body weight, morbid obesity, diet, drug treatment

REFERENCES

Ametov A.S. (2013) Effective treatment of obesity: ways to fight epidemic of diabetes mellitus. Meditsinskiy sovet = Medical Council., 2(2): 78-83;   doi: 10.21518/2079-701X-2013-2-2-78-83(in Russian). 

Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., Hazlehurst J.M., Guo K., Abouda G., Aldersley M.A., Stocken D., Gough S.C.,  Tomlinson J.W., Brown R.M., Hübscher S.G., Newsome Ph.N. (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. The Lancet, 387(10019): 679-690.  doi: 10.1016/S0140-6736(15)00803-x.

Askerov F.B. (2018) From the receptor to the reflex. Baku: 419 p. (in Russian).

Astrup A., Grunwald G.K., Melanson E.L., Saris W.H.M., Hill J.O. (2000) The role of low-fat diets in body weight control: a meta-analysis of ad libitum dietary intervention studies, International Journal of Obesity, 24(12): 1545-1552. doi.org/10.1038/sj.ijo.0801453.

Barte J.C.M., Ter Bogt N.C.W. Bogers R.P., Teixeira P.J., Blissmer B., Mori T.A., Bemelmans W.J.E. (2010) Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obesity Reviews, 11(12): 899-906. doi.org/10.1111/j.1467-789X.2010.00740.x

Buturova S.A. (2004) Obesity therapy. In book: Obesity: Etiology, Pathogenesis, Clinical Aspects: A Guide for Physicians (Ed. by I.I.Dedov, G.A.Melnichenko) Moscow: Medical News Agency, p. 378-405 (in Russian).

Eckard C., Cole R., Lockwood J., Torres D.M., Williams Ch.D., Shaw J.C., Harrison S.A. (2013) Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic Advances in Gastroenterology, 6(4): 249-259. doi: 10.1177/1756283X13484078

Florentin M., Liberopoulos E.N., Elisaf M.S. (2008) Sibutramine‐associated adverse effects: a practical guide for its safe use. Obesity Reviews, 9(4): 378-387.

Harrison S.A., Fecht W., Brunt E.M., Neuschwander‐Tetri B.A. (2009) Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology, 49(1): 80-86.  doi: 10.1002/ hep.22575.

Heijden G.-J., Wang Z.J., Chu Z.D., Sauer P.J. J., Haymond M.W.,  Rodriguez L.M., Sunehag A.L. (2010) A 12-week Aerobic Exercise Program Reduces Hepatic Fat Accumulation and Insulin Resistance in Obese, Hispanic Adolescents. Obesity, 18(2): 384-390. doi: 10.1038/oby.2009.274

James W.Ph.T., Caterson I.D., Coutinho W., Finer N., Gaal L.F.V., Maggioni A.P., Torp-Pedersen Ch., Sharma A.M., Shepherd G.M., Rode R.A.,  Renz Ch.L., SCOUT Investigators. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England journal of medicine, 363(10): 905-917. doi: 10.1056/NEJMoa1003114.Jensen M.D., Ryan D.H., Apovian C.M., Ard J.D., Comuzzie A.G., Donato K.A., Hu F.B., Hubbard V.S., Jakicic J.M., Kushner R.F., Loria C.M., Millen B.E., Nonas C.A., Pi-Sunyer F.X., Stevens J., Stevens V.J., Wadden Th.A., Wolfe B.M., Yanovski S.Z. (2014) 2013 AHA/ACC/TOS Guideline for the management of overweight and obesity in adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, 129(25): S102–S138.  doi: 10.1161/01.cir.0000437739.71477.ee

Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J.,  Lucia M.S., Goodman Ph.J.,  Minasian L., Ford L.G.,  Parnes H.L.,  Gaziano J. M., Karp D.D., Lieber M.M., Walther Ph.J., Klotz L.,  Parsons J.K., Chin J.L., Darke A.K., Lippman S.M., Goodman G.E., Meyskens F.L., Baker L.H. (2011) Vitamin E and the Risk of Prostate Cancer: Updated Results of The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA, 306(14): 1549–1556. doi: 10.1001/jama.2011.1437.

Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L.A., Konev Yu.V., Seliverstov P.V., Sitkin S.I., Tkachenko E.I., Avalueva E.B., Ailamazyan E.K., Vlasov N.N., Grinevich V.B., Kornienko E.A., Novikova V.P., Khoroshinina L.P., Zhestkova N.V., Oreshko L.S., Dudanova O.P., Dobritsa V.P., Turyeva L.V., Tirikova O.V., Kozlova N.M., Eliseev S.M., Gumerov R.R., Ventsak E.V., Aleshina E.I., Gurova M.M., Goryacheva L.G. (2017) Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (recommendations for therapist, 2nd edition). Eksperimental’naya i Klinicheskaya Gastroenterologiya, 138 (2): 22–37 (in Russian).

Lee H.-K., Choi E.B., Pak Ch.S. (2009) The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Current topics in medicinal chemistry, 9(6): 482-503. doi: 10.2174/156802609788897844.

Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., Franklin B., Kris-Etherton P., Harris W.S., Howard B., Karanja N., Lefevre M., Rudel L., Sacks F., Van Horn L., Winston M., Wylie-Rosett J. (2006) Diet and Lifestyle Recommendations Revision 2006. A Scientific Statement from the American Heart Association Nutrition Committee. Circulation, 114(1): 82-96. doi: 10.1161/CIRCULATIONAHA.106.176158

Magkos F. (2010) Exercise and fat accumulation in the human liver. Current opinion in lipidology, 21(6): 507-517.

Marra F., Lotersztajn S. (2013) Pathophysiology of NASH: Perspectives for a Targeted Treatment. Current Pharmaceutical Design, 19(29): 5250-5269. doi: 10.2174/13816128113199990344

Michka V.B., Blinova N.V., Gornostaev V.V., Sergienko V.B., Ataullahanova D.M., Masenko V.P., Chazova I.E. (2010) Drug treatment obesity in patient’s metabolic syndrome. Effective pharmacotherapy. Cardiology and Angiology, 2: 38-43 (in Russian).

Nerobeev V.D. (2014) Pharmacotherapy and surgical treatment of obesity in the structure of modern medical-social problems of diseases of civilization. Newspaper “Medicine and pharmacy news”, 503-504(9-10): 18-20 (in Ukrainian).

Petta S., Marchesini G., Caracausi L.,  Macaluso F.S. Cammà C., Ciminnisi S., Cabibi D.,  Porcasi R., Craxì A., Marco V.D. (2013) Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. Journal of Hepatology, 59(6): 1169-1176.  doi: 10.1016/j.jhep.2013.07.037

Popov V.B., Lim J.K. (2015) Treatment of nonalcoholic fatty liver disease: The role of medical, surgical, and endoscopic weight loss. Journal of Clinical and Translational Hepatology, 3(3): 230-238.

Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 51(1): 121-129.  doi: 10.1002/hep.23276

Ratziu V., Giral P., Jacqueminet S., Charlotte F., Hartemann–Heurtier A., Serfaty L. Podevin P., Lacorte J.–M., Bernhardt C., Bruckert E., Grimaldi A., Thierry Poynard LIDO Study Group. (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology, 135(1): 100-110.  doi: 10.1053/j.gastro.2008.03.078

Romantsova T.I., Poluboyarinova I.V., Roik O.V. (2012) Dynamics of adipose tissue changes measured by MRI in obese patients during Reduxin treatment. Obesity and metabolism, 9(4): 39-43 (in Russian).

Ryan D.H., Johnson W.D., Myers V.H, Prather T.L., McGlone M.M., Rood J., Brantley Ph.J., Bray G.A., Gupta A.K., Broussard A.P., Barootes B.G., Elkins B.L., Gaudin D.E., Savory R.L., Brock R.D., Datz G., Pothakamuri S.R, McKnight G.T., Stenlof K., Sjöström L.V. (2010) Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings: Results of the Louisiana Obese Subjects Study. Archives of Internal Medicine, 170(2): 146-154. doi: 10.1001/archinternmed.2009.508.

Ryttig K., Rössner S. (1995) Weight meitenance after a very low calorie diet (VLCD) weight reduction period and the effects of VLCD supplementation. A prospective, randomized, comparative, controlled long-term trial. Journal of Internal Medicine, 238(4): 299-306. doi: 10.1111/j.1365-2796. 1995. tb01202.x.

Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., Neuschwander-Tetri B.A., Lavine J.E., Tonascia J., Unalp A., Natta M.V., Clark J., Brunt E.M., Kleiner D.E., Hoofnagle J.H., Robuck P.R. (2010) Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis. The New England journal of medicine, 362(18): 1675-1685. doi: 10.1056/NEJMoa0907929.

Savelieva L.V. (2011) Modern concept of treatment of obesity. Obesity and metabolism, 1: 51-56 (in Russian).

Simopoulos A.P. (2013) Dietary omega-3 Fatty Acid Deficiency and High Fructose Intake in the Development of Metabolic Syndrome, Brain Metabolic Abnormalities, and Non-Alcoholic Fatty Liver Disease. Nutrients, 5(8): 2901-2923. doi: 10.3390/nu5082901

Starostina E.G. (2011) Problems of treatment of patients with morbid obesity. Obesity and metabolism, 8(1): 57-66 (in Russian).

Summerbell C.D., Cameron C., Glasziou P.P. (2008) WITHDRAWN: Advice on Low-Fat Diets for Obesity. Cochrane Database Syst. Rev., 16(3): CD003640.

Takahashi Y., Sugimoto K., Inui H., Fukusato T. (2015) Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology. 21(13): 3777-3785. doi: 10.3748/wjg.v21.i13.3777

Takeshita Y., Takamura T. Honda M., Kita Y., Zen Y.,  Kato K., Misu H., Ota T., Nakamura M., Yamada K., Sunagozaka H., Arai K., Yamashita T., Mizukoshi E., Kaneko Sh. (2014) The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia, 57(5): 878–890.

Timofeeva N.M., Egorova V.V., Nikitina A.A. (2008) Quality of nutrition during pregnancy or lactation programs functioning of enzyme systems of digestive and non-digestive organs in “Grandchildren” during their adult life. Journal of Evolutionary Biochemistry and Physiology, 44(2): 254–257.

Tishkovskiy S.V., Nikonova L.V., Doroshkevich I.P. (2015) Modern approaches to treatment of obesity. Journal of the Grodno State Medical University, 2: 134-139 (in Russian).

Vlasova Yu.Yu, Ametov A.S. (2012) The influence of sibutramine therapy on the body composition and metabolic characteristics of the patients presenting with exogenous constitutional obesity. Endocrinology Problems, 1: 34-38 (in Russian).

Wong V.W.-S., Chan R.S.-M., Wong G.L.-H., Cheung B.H.-K., Chu W.Ch.-W., Yeung D.K.-W., Chim A.M.-L., Lai J.W.-Y., Li L.S., Sea M.M.-M., Chan F.K.-L., Sung J.J.-Y., Woo J.,  Chan Henry L.-Y. (2013) Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. Journal of Hepatology, 59(3): 536-542. doi: 10.1016/j.jhep.2013.04.013

Yoneda M., Fujita K., Nozaki Y., Endo H., Takahashi H., Hosono K., Suzuki K., Mawatari H., Kirikoshi H., Inamori M., Saito S., Iwasaki T., Terauchi Y., Kubota K., Maeyama Sh., Nakajima A. (2010) Efficacy of Ezetimibe for the Treatment of Non-Alcoholic Steatohepatitis: An Open-Label, Pilot Study. Hepatology Research: the official journal of the Japan Society of Hepatology, 40(6): 566-73. doi: 10.1111/j.1872-034X.2010.00644.x.

Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology, 63(1): 73-84. doi: 10.1002/hep.28431

Zein C.O., Yerian L.M., Gogate P., Lopez R., Kirwan J.P., Feldstein A.E., McCullough A.J. (2011) Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo ‐ controlled trial. randomized, prospective trial. Hepatology, 54(5): 1610-1619.  doi: 10.1002/hep.24544.

Zhirkov I.I., Gordienko A.V., Gulyaev N.I., Serdyukov D.Yu., Stepanova A.A. (2019) Chronic diffuse liver disease of non-viral etiology in the military. Bulletin of the Russian Military-Medical Academy, 68(4): 72-76 (in Russian).